References
- BerrySJCoffeyDSWalshPCEwingLLThe development of human benign prostatic hyperplasia with ageJ Urol19841324744796206240
- GarrawayWMCollinsGNLeeRJHigh prevalence of benign prostatic hypertrophy in the communityLancet19913384694711714529
- McVaryKTRoehrbornCGAvinsALUpdate on AUA guideline on the management of benign prostatic hyperplasiaJ Urol20111851793180321420124
- MadersbacherSAlivizatosGNordlingJEAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines)Eur Urol20044654755415474261
- McVaryKTAlfuzosin for symptomatic benign prostatic hyperplasia: long-term experienceJ Urol2006175354216406865
- RoehrbornCGBruskewitzRNickelGCUrinary retention in patients with BPH treated with finasteride or placebo over 4 years – characterization of patients and ultimate outcomesEur Urol20003752853610765090
- KearneyPMWheltonMReynoldsKMuntnerPWheltonPKHeJGlobal burden of hypertension: analysis of worldwide dataLancet200536521722315652604
- MondainiNGiubileiGUngarAAlfuzosin (10mg) does not affect blood pressure in young healthy menEur Urol2006501292129816837126
- KaplanSAUroselective alpha-blockade for benign prostatic hyperplasia: clinically significant or marketing savvy?Urology19995477677910565732
- ChauLHTaiDCFungBTLiJCFanCWLiMKMedical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10 mm: a prospective randomized controlled trialInt J Urol20111851051421592234
- AhmedAFAl-SayedAYTamsulosin versus alfuzosin in the treatment of patients with distal ureteral stones: prospective, randomized, comparative studyKorean J Urol20105119319720414396
- MehikAAlasPNickelJCSarpolaAHelströmPJAlfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot studyUrology20036242542912946740
- BasarMMAtanAOzerginOYildizMThe efficacy of alfuzosin treatment in patients with prostatismInt Urol Nephrol20013349349712230279
- RoweESmithCLaverickLElkabirJWitherowROPatelAA prospective, randomized, placebo controlled, double-blind study of pelvic electromagnetic therapy for the treatment of chronic pelvic pain syndrome with 1 year of followupJ Urol20051732044204715879822
- MichelMCHeemannUSchumacherHMehlburgerLGoepelMAssociation of hypertension with symptoms of benign prostatic hyperplasiaJ Urol20041721390139315371852
- AUA Practice Guidelines CommitteeAUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendationJ Urol20031702 Pt 153054712853821
- SongKChooMSLeeKSThe long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractilityUrology2011771177118221256567
- VallancienGEmbertonMAlcarazAALF-ONE Study GroupAlfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practiceBJU Int200810184785218321317
- RoehrbornCGAlfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled studyBJU Int20069773474116536764
- NickelJCElhilaliMEmbertonMVallancienGAlf-One Study GroupThe beneficial effect of alfuzosin 10 mg once daily in ‘real-life’ practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculationBJU Int2006971242124616686719
- NordlingJEfficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasiaBJU Int2005951006101215839922
- MottetNBressolleFDelmasVRobertMCostaPProstatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administrationEur Urol20034410110512814682
- ElhilaliMEmbertonMMatzkinHLong-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in ‘real-life’ practiceBJU Int20069751351916469018
- RoehrbornCVan KerrebroeckPNordlingJSafety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studiesBJU Int20039225726112887479
- van KerrebroeckPJardinAvan CanghPLavalKUALFORTI Study GroupLong-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension studyEur Urol200241546011999466
- LeeSHParkKKMahSYEffects of alpha-blocker ‘add on’ treatment on blood pressure in symptomatic BPH with or without concomitant hypertensionProstate Cancer Prostatic Dis20101333333720567256